Bone fragility craniosynostosis proptosis hydrocephalus

From WikiMD's Food, Medicine & Wellness Encyclopedia

Bone Fragility Craniosynostosis Proptosis Hydrocephalus (BFCH) is a rare genetic disorder characterized by a combination of symptoms including bone fragility, craniosynostosis, proptosis, and hydrocephalus. This condition is caused by mutations in the SEC24D gene.

Symptoms[edit | edit source]

The primary symptoms of BFCH include:

  • Bone Fragility: This refers to a condition where the bones are more fragile than normal, leading to an increased risk of fractures.
  • Craniosynostosis: This is a condition where the sutures in a baby's skull close earlier than normal, which can affect the shape of the head and the development of the brain.
  • Proptosis: This is a condition where the eyes bulge out of the eye sockets, often due to swelling or growths.
  • Hydrocephalus: This is a condition where there is an accumulation of cerebrospinal fluid in the brain, causing increased pressure and swelling.

Causes[edit | edit source]

BFCH is caused by mutations in the SEC24D gene. This gene is involved in the transport of proteins from the endoplasmic reticulum to the Golgi apparatus, a process known as protein trafficking. Mutations in this gene disrupt this process, leading to the symptoms of BFCH.

Diagnosis[edit | edit source]

Diagnosis of BFCH is based on the presence of the characteristic symptoms and confirmed by genetic testing to identify mutations in the SEC24D gene.

Treatment[edit | edit source]

Treatment for BFCH is symptomatic and supportive. This may include surgery to correct craniosynostosis, treatment for bone fragility, and management of hydrocephalus.

See Also[edit | edit source]

Template:Bone-disease-stub Template:Craniofacial-abnormalities-stub

Template:Brain-disorder-stub

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Admin, Prab R. Tumpati, MD